, Volume 28, Issue 4, pp 309–318 | Cite as

5-Hydroxyindoleacetic acid (5 HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines

  • Malcolm B. BowersJr.
Original Investigations Human Pharmacology


Lumbar CSF 5 HIAA and HVA were measured following probenecid administration in acute psychotic patients before and during treatment with phenothiazines. Patients with more classical schizophrenic symptoms had higher values for 5 HIAA/HVA than other psychotics, depressives, and inmate volunteers. Prior to treatment CSF 5 HIAA, but not HVA, correlated significantly with several clinical items related to psychotic disorganization. Phenothiazine treatment produced significant increases in CSF HVA which could not be correlated with the dose of antipsychotic or antiparkinson drugs.

Key words

5-Hydroxyindoleacetic Acid Homovanillic Acid CSF Psychosis Phenothiazines Probenecid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aghajanian, G. K.: Influence of drugs on the firing of serotonin-containing neurons in brain. Fed. Proc. 31, 91–96 (1972).Google Scholar
  2. Anden, N.-E., Roos, B.-E., Werdinius, B.: Effects of chlorpromazine, haloperidol, and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci. 3, 149–158 (1964).Google Scholar
  3. Bowers, M. B., Jr.: Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of CSF acid monoamine metabolite measures. Neuropharmacol. 23, 26–33 (1972a).Google Scholar
  4. Bowers, M. B., Jr.: CSF 5-HIAA and HVA following probenecid in unipolar depressives treated with amitriptyline. Psychopharmacologia (Berl.) 23, 26–33 (1972b).Google Scholar
  5. Bowers, M. B., Jr.: Acute Psychosis induced by psychotomimetic drug abuse II. Neurochemical Findings. Arch. gen. Psychiat. 27, 440–442 (1972).Google Scholar
  6. Bowers, M. B., Jr., Heninger, G. R., Gerbode, F. A.: CSF 5-HIAA and HVA in psychiatric patients. Int. J. Neuropharmacol.. 8, 255–262 (1969).Google Scholar
  7. Bowers, M. B., Jr., Roth, R. H.: Interaction of atropine-like drugs with dopaminecontaining neurons in rat brain. Brit. J. Pharmacol. 44, 301–306 (1972).Google Scholar
  8. Bruno, A., Allegranza, A.: The effect of haloperidol on the urinary excretion of dopamine, homovanillic, and vanilmandelic acids in schizophrenics. Psychopharmacologia (Berl.) 8, 60–66 (1965).Google Scholar
  9. Chase, T. N., Schnur, J. A., Gordon, E. K.: CSF monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacol. 9, 265–268 (1970).Google Scholar
  10. Gerbode, F. A., Bowers, M. B., Jr.: Measurement of acid monoamine metabolites in human and animal CSF. J. Neurochem. 15, 1053–1055 (1968).Google Scholar
  11. Korf, J., Van Praag, H. M.: Amine metabolism in the human brain: further evaluation of the probenecid test. Brain Res. 35, 221–230 (1971).Google Scholar
  12. Kupfer, D. J., Detre, T. P., Foster, F. G., Tucker, G. J., Delgado, J.: The application of Delgado's telemetric mobility recorder for human studies. Behav. Biol. 7, 585–590 (1972).Google Scholar
  13. Mellor, C. S.: The first rank symptoms of schizophrenia. Brit. J. Psychiat. 117, 15–23 (1970).Google Scholar
  14. Moir, A. T. B., Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Guldberg, H. C.: Cerebral metabolites in CSF as a biochemical approach to the brain. Brain 93, 357–368 (1970).Google Scholar
  15. O'Keefe, R., Sharman, D. F., Vogt, M.: Effect of drugs used in psychoses on cerebral dopamine metabolism. Brit. J. Pharmacol. 38, 287–304 (1970).Google Scholar
  16. Persson, T., Roos, B.-E.: Acid metabolites from monoamines in CSF of chronic schizophrenics. Brit. J. Psychiat. 115, 95–98 (1969).Google Scholar
  17. Rimon, R., Roos, R.-E., Rakkolainen, V., Alanen, Y.: The content of 5-HIAA and HVA in the CSF of patients with acute schizophrenia. J. Psychosom. Res. 15, 375–378 (1971).Google Scholar
  18. Robins, E., Guze, S. B.: Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Amer. J. Psychiat. 126, 983–987 (1970).Google Scholar
  19. Stephens, J. H., Astrup, C., Mangrum, J. C.: Prognostic factors in recovered and deteriorated schizophrenics. Amer. J. Psychiat. 122, 1116–1120 (1966).Google Scholar
  20. Tamarkin, N. R., Goodwin, F. K., Axelrod, J.: Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sci. 9, 1397–1408 (1970).Google Scholar
  21. Taylor, M. A.: Schneiderian first rank symptoms and clinical prognostic features in schizophrenia. Arch. gen. Psychiat. 26, 64–67 (1972).Google Scholar
  22. Van Praag, H. M., Korf, J.: Retarded depression and the dopamine metabolism. Psychopharmacologia (Berl.) 19, 199–203 (1971).Google Scholar

Copyright information

© Springer-Verlag 1973

Authors and Affiliations

  • Malcolm B. BowersJr.
    • 1
    • 2
  1. 1.Department of PsychiatryYale UniversityUSA
  2. 2.The Connecticut Mental Health CenterNew HavenUSA

Personalised recommendations